Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos secures milestone payment in osteoarthritis alliance
As per the partnership deal, Galapagos is responsible for the discovery and development of new candidate drugs, and Servier has an exclusive option to license the drugs after
As per the partnership deal, Galapagos is responsible for the discovery and development of new candidate drugs, and Servier has an exclusive option to license the drugs after
Actemra is the first humanized IL-6 receptor-inhibiting monoclonal antibody approved for the treatment of adult patients with moderately to severely active RA and for the treatment of active
The two-dose six week Phase 2 study will enroll 150 men to evaluate the effect of both low and high doses of NX-1207 on low grade localized prostate
The BenchMark XT instrument, the HER2 Dual ISH assay, is now approved for use on both Ventana BenchMark advanced staining platforms available in the US. The HER2 Dual
Inhibition of ALDH2 activity, a key enzyme in ethanol metabolism, through the silencing of ALDH2, results in the build-up of acetaldehyde, which causes adverse physiological effects that cause
The new plant, which will produce Ensure and Glucerna for the North America market, is expected to become operational in late 2013. The new manufacturing facility will specialize
Ultresa (Pancrelipase) delayed release capsules are indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis (CF) or other conditions. Viokace (Pancrelipase) tablets are indicated for
Fabrazyme is approved for treatment of Fabry disease, an inherited condition that is characterized by excessive accumulation of the lipid GL-3 in various organs and tissues. Patients in
The partnership will allow Cheminnova to gain significant stake in exchange for the intellectual property rights for RNL’s product range for some markets and the manufacturing rights for
Acceliant, a comprehensive clinical data management platform, will support Phase I-IV trials and post-marketing studies for all therapeutic areas and medical devices. The solution supports a clinical trial